Respiratory syncytial virus (RSV) may pose a significant health risk, particularly for older adults and those with certain underlying health conditions. Educating ourselves and others can help protect the most vulnerable populations from this illness. To raise global awareness of the virus, we're thrilled to announce the launch of #GlobalRSVAwarenessWeek, a crucial initiative alongside the COPD Foundation, Global Allergy & Airways Patient Platform and International Federation on Ageing. As part of this week-long awareness momentum, we’ve released results of a GSK-funded online survey of 3,516 respondents in four countries about awareness of and attitudes towards RSV, the results of which highlighted the urgent need for increased awareness. Join us in this global effort to combat RSV by reading and sharing the survey results. Together, we can make a difference! Learn more about RSV: https://gsk.me/4g7x7gB 👈
關於我們
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia
- 網站
-
http://www.gsk.com
外部葛兰素史克公司連結
- 產業
- 製藥製造
- 公司規模
- 10,001+ 名員工
- 總部
- BrentfordMiddlesex
- 類型
- 上市公司
- 專長
- Pharmaceutical products和Vaccines
地點
葛兰素史克公司員工
動態消息
-
#News for #investors and #media: At #ERSCongress2024 we’ll be sharing our latest research across 56 abstracts including a late breaking alert session. We are redefining the future of respiratory medicine by building on decades of expertise to deliver ambitious, next generation treatment goals for hundreds of millions of people living with a variety of respiratory diseases like #asthma and #COPD. Learn more here: https://gsk.to/4e7vo99
-
Have you heard of respiratory syncytial virus or RSV? Six in 10 adults over the age of 50 haven’t, according to our new survey – despite some being among the groups most at risk of infection. RSV is a contagious virus that infects the nose, throat, lungs and airways. Whilst appearing as a mild cold for most, it can be life-threatening for babies, older people and those with underlying medical conditions. For this reason, being educated on the risks of RSV is essential. Find out what else we learned from our multi-country survey here: https://gsk.to/4d5QnIR
-
-
[For Healthcare Professionals only] Are you attending the #ERSCongress2024 in Vienna next week? We’re looking forward to joining you along with two experts in respiratory diseases – Dr Cedric ‘Jamie’ Rutland and Professor Alberto Papi. They’ll both be on our GSK medical booth during the congress to discuss the latest in preventing and managing different respiratory illnesses – learn more in the video below, and please join us if you’re attending ERS.
-
GSK’s Africa Open Lab is making a real difference in addressing the knowledge gaps of how infectious diseases affect people in Africa. African-led research is vital in helping understand how diseases such as TB and malaria present amongst African populations, and how people respond to medicines. By partnering with, and supporting, local researchers and scientists, we can create a positive impact and make a meaningful difference in the lives of millions across Africa, and beyond. Discover the incredible impact of the Africa Open Lab to date, by hearing from some of the recipients themselves and dive into our latest Impact Partnerships report: https://gsk.to/3Mrs7WG
-
Siaya, a county in western Kenya, sits on the shores of Lake Victoria and its communities live off the lake and its wildlife. But its children are under threat from malaria – a disease that kills a child under five every minute. Ensuring these communities are protected is more than needed – it’s critical. Yet despite this, global health progress has slowed. Here, our Chief Global Health Officer Thomas Breuer, MD, MSc explains the importance of supporting communities like Siaya to thrive by making sure we’re keeping our feet on the accelerator: https://gsk.to/3YTJmqQ
-
-
News for #investors and #media: Today, we have announced that the European Commission has approved an expanded indication for one of our vaccines. Learn more: https://gsk.to/3T6SlBk
-
-
Forebygging på agendaen, hva er det vi venter på?
For å sikre at eldre kan leve gode liv og forbli en aktiv del av samfunnet, er det viktig at de holder seg friske lengst mulig. 🌼 Vaksinasjon er en enkel måte å forebygge sykdommer på. Derfor haster det å få på plass et voksenvaksinasjonsprogram. Vi mener alle skal ha mulighet til å beskytte seg og sine kjære gjennom vaksinasjon. Sosial ulikhet i helse er økende, og det er derfor viktig at alle uansett bosted, bakgrunn eller økonomi får like muligheter. 🧡 Eldre fortjener å leve gode liv – hele livet. #forebygging #voksenvaksinasjonsprogram #vaksinasjon #sunnaldring #ansvarligaldring
Les mer på sykdomsinfo.no
-
#News for #investors and #media: Today we announced that one of our investigational medicines has been granted SENKU designation by the Japanese Ministry of Health, Labour and Welfare (MHLW). Find out more https://gsk.to/3yVDq6d
-
#News for #investors and #media: Today we have announced that Japan has approved the use of one of our biologics as a treatment option for people with chronic rhinosinusitis and nasal polyps (#CRSwNP). Learn more here: https://gsk.to/3yWnj8o